World's Best Scientists 2026 revealed!

D-Index & Metrics

Microbiology

D-Index
57
Citations
11229
World Ranking
3589
National Ranking
316

Graeme Moyle publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Graeme Moyle sits on this spectrum.

55–64 publications: 8 scientists 65–74 publications: 29 scientists 75–84 publications: 55 scientists 85–94 publications: 112 scientists 95–104 publications: 137 scientists 105–114 publications: 190 scientists 115–124 publications: 235 scientists 125–134 publications: 234 scientists 135–144 publications: 288 scientists 145–154 publications: 264 scientists 155–164 publications: 264 scientists 165–174 publications: 253 scientists 175–184 publications: 276 scientists 185–194 publications: 190 scientists 195–204 publications: 233 scientists 205–214 publications: 207 scientists 215–224 publications: 198 scientists 225–234 publications: 155 scientists 235–244 publications: 161 scientists 245–254 publications: 160 scientists 255–264 publications: 146 scientists 265–274 publications: 139 scientists 275–284 publications: 148 scientists 285–294 publications: 115 scientists 295–304 publications: 96 scientists 305–314 publications: 88 scientists 315–324 publications: 106 scientists 325–334 publications: 65 scientists 335–344 publications: 76 scientists 345–354 publications: 64 scientists 355–364 publications: 62 scientists 365–374 publications: 65 scientists 375–384 publications: 61 scientists 385–394 publications: 34 scientists 395–404 publications: 44 scientists 405–414 publications: 36 scientists 415–424 publications: 35 scientists 425–434 publications: 29 scientists 435–444 publications: 33 scientists 445–454 publications: 34 scientists 455–464 publications: 25 scientists 465–474 publications: 26 scientists 475–484 publications: 20 scientists 485–494 publications: 19 scientists 495–504 publications: 16 scientists 505–514 publications: 17 scientists 515–524 publications: 23 scientists 525–534 publications: 14 scientists 535–544 publications: 14 scientists 545–554 publications: 18 scientists 555–564 publications: 12 scientists 565–574 publications: 7 scientists 575–584 publications: 9 scientists 585–594 publications: 9 scientists 595–604 publications: 9 scientists 605–614 publications: 7 scientists 615–624 publications: 9 scientists 625–634 publications: 7 scientists 635–644 publications: 4 scientists 645–654 publications: 5 scientists 655–664 publications: 6 scientists 665–674 publications: 7 scientists 675–678 publications: 3 scientists 679+ publications: 99 scientists
55 publications 679+

This scientist: 257 publications — 67th percentile

67% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 679 publications or more.

Graeme Moyle D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Graeme Moyle sits on this spectrum.

40 D-Index: 30 scientists 41 D-Index: 86 scientists 42 D-Index: 90 scientists 43 D-Index: 117 scientists 44 D-Index: 122 scientists 45 D-Index: 123 scientists 46 D-Index: 108 scientists 47 D-Index: 110 scientists 48 D-Index: 106 scientists 49 D-Index: 109 scientists 50 D-Index: 129 scientists 51 D-Index: 111 scientists 52 D-Index: 116 scientists 53 D-Index: 127 scientists 54 D-Index: 134 scientists 55 D-Index: 134 scientists 56 D-Index: 111 scientists 57 D-Index: 136 scientists 58 D-Index: 162 scientists 59 D-Index: 151 scientists 60 D-Index: 139 scientists 61 D-Index: 122 scientists 62 D-Index: 126 scientists 63 D-Index: 144 scientists 64 D-Index: 109 scientists 65 D-Index: 103 scientists 66 D-Index: 124 scientists 67 D-Index: 112 scientists 68 D-Index: 103 scientists 69 D-Index: 131 scientists 70 D-Index: 93 scientists 71 D-Index: 93 scientists 72 D-Index: 96 scientists 73 D-Index: 92 scientists 74 D-Index: 80 scientists 75 D-Index: 66 scientists 76 D-Index: 87 scientists 77 D-Index: 60 scientists 78 D-Index: 73 scientists 79 D-Index: 59 scientists 80 D-Index: 57 scientists 81 D-Index: 55 scientists 82 D-Index: 47 scientists 83 D-Index: 77 scientists 84 D-Index: 50 scientists 85 D-Index: 45 scientists 86 D-Index: 42 scientists 87 D-Index: 41 scientists 88 D-Index: 32 scientists 89 D-Index: 38 scientists 90 D-Index: 35 scientists 91 D-Index: 34 scientists 92 D-Index: 27 scientists 93 D-Index: 26 scientists 94 D-Index: 33 scientists 95 D-Index: 22 scientists 96 D-Index: 37 scientists 97 D-Index: 22 scientists 98 D-Index: 21 scientists 99 D-Index: 22 scientists 100 D-Index: 30 scientists 101 D-Index: 16 scientists 102 D-Index: 20 scientists 103 D-Index: 17 scientists 104 D-Index: 19 scientists 105 D-Index: 16 scientists 106 D-Index: 19 scientists 107 D-Index: 18 scientists 108 D-Index: 14 scientists 109 D-Index: 10 scientists 110 D-Index: 9 scientists 111 D-Index: 7 scientists 112 D-Index: 11 scientists 113 D-Index: 6 scientists 114 D-Index: 15 scientists 115 D-Index: 10 scientists 116 D-Index: 12 scientists 117 D-Index: 7 scientists 118 D-Index: 10 scientists 119 D-Index: 10 scientists 120 D-Index: 11 scientists 121 D-Index: 2 scientists 122 D-Index: 7 scientists 123 D-Index: 12 scientists 124 D-Index: 5 scientists 125 D-Index: 9 scientists 126 D-Index: 6 scientists 127+ D-Index: 95 scientists
40 D-Index 127+

This scientist: 57 D-Index — 36th percentile

36% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 127 D-Index or more.

Overview

Graeme Moyle is affiliated with the Chelsea and Westminster Hospital NHS Foundation Trust in the United Kingdom. The primary field of their research is Medicine, with a focus on HIV-related health complications and treatments.

The scientist's work covers several subfields, including Emergency Medicine, Infectious Diseases, Endocrinology, Diabetes and Metabolism, Virology, and Surgery. Their research topics emphasize HIV-related health complications and treatments, HIV/AIDS drug development and treatment, HIV Research and Treatment, Lipoproteins and Cardiovascular Health, Diabetes, Cardiovascular Risks, and Lipoproteins, HIV/AIDS Research and Interventions, and Pharmacological Effects and Toxicity Studies.

Frequent coauthors collaborating with Moyle include:

  • Christoph Stephan
  • Mar Masiá
  • Éric Florence
  • Estebán Martínez
  • Christine Katlama

The scientist has published extensively in various venues, with repeated contributions to several journals. Their frequent publication venues are:

  • Journal of Antimicrobial Chemotherapy
  • Clinical Infectious Diseases
  • JAIDS Journal of Acquired Immune Deficiency Syndromes
  • HIV Medicine
  • Open Forum Infectious Diseases

Recent papers authored or coauthored by Graeme Moyle include:

  • Evolocumab in HIV-Infected Patients With Dyslipidemia, 2020, Journal of the American College of Cardiology
  • Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV, 2020, PLoS ONE
  • Antiretrovirals and Weight Change: Weighing the Evidence, 2024, Clinical Infectious Diseases
  • Feasibility randomized-controlled trial of online acceptance and commitment therapy for painful peripheral neuropathy in people living with HIV: The OPEN study, 2021, European Journal of Pain
  • Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV, 2021, Journal of Antimicrobial Chemotherapy

Best Publications

  • Antiretroviral therapy for HIV infection. A knowledge-based approach to drug selection and use.

    Graeme J. Moyle;Brian G. Gazzard;David A. Cooper;José Gatell

  • Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

    Jean-Michel Molina;Jaime Andrade-Villanueva;Juan Echevarria;Ploenchan Chetchotisakd

  • Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy.

    Mark E. Sharkey;Ian Teo;Thomas Greenough;Natalia Sharova

  • A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy.

    Graeme J. Moyle;Caroline A. Sabin;Jonathan Cartledge;Margaret Johnson

  • Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study.

    Jean-Michel Molina;Jaime Andrade-Villanueva;Juan Echevarria;Ploenchan Chetchotisakd

  • Epidemiology and Predictive Factors for Chemokine Receptor Use in HIV-1 Infection

    Graeme J. Moyle;Adrian Wildfire;Sundhiya Mandalia;Howard Mayer

  • Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study.

    Frank A Post;Graeme J Moyle;Hans Jürgen Stellbrink;Pere Domingo

  • Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity

    Graeme Moyle

  • Loss of Discrete Memory B Cell Subsets Is Associated with Impaired Immunization Responses in HIV-1 Infection and May Be a Risk Factor for Invasive Pneumococcal Disease

    Melanie Hart;Alan Steel;Sally A. Clark;Graeme Moyle

  • Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors.

    Graeme J Moyle;Debasis Datta;Sundhiya Mandalia;John Morlese

  • Safety and Immunogenicity of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in HIV-Infected Adults: A Phase 1/2a Randomized, Placebo-Controlled Study

    Elchonon M. Berkowitz;Graeme Moyle;Hans-Jürgen Stellbrink;Dirk Schürmann

  • Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data.

    Mario Cruciani;Veronica Zanichelli;Giovanni Serpelloni;Oliviero Bosco

  • Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study.

    Rachael Jones;Justin Stebbing;Mark Nelson;Graeme Moyle

  • Current knowledge and future prospects for the use of HIV protease inhibitors.

    Graeme Moyle;Brian G. Gazzard

  • The Impact of HIV Tropism on Decreases in CD4 Cell Count, Clinical Progression, and Subsequent Response to a First Antiretroviral Therapy Regimen

    Laura Waters;Sundhiya Mandalia;Paul Randell;Adrian Wildfire

  • Antiretroviral nucleoside and nucleotide analogues and mitochondria.

    Andrea Cossarizza;Graeme Moyle

  • A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy

    G J Moyle;C Baldwin;B Langroudi;S Mandalia

  • Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy.

    Graeme J. Moyle;Michelle Lloyd;Brian Reynolds;Christine Baldwin

  • Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1–Infected Patients: Week 48 Results

    Joel E. Gallant;Ellen Koenig;Jaime Andrade-Villanueva;Ploenchan Chetchotisakd

  • Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study.

    Graeme J Moyle;Edwin DeJesus;Pedro Cahn;Steve A Castillo

  • Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial.

    Richard B. Pollard;Jürgen K. Rockstroh;Giuseppe Pantaleo;David M. Asmuth

  • Toxicity of antiretroviral nucleoside and nucleotide analogues: is mitochondrial toxicity the only mechanism?

    Graeme Moyle

  • Effects of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analog, in Human Immunodeficiency Virus-Infected Patients with Excess Abdominal Fat: A Pooled Analysis of Two Multicenter, Double-Blind Placebo-Controlled Phase 3 Trials with Safety Extension Data

    Julian Falutz;Jean-Claude Mamputu;Diane Potvin;Graeme Moyle

  • Peripheral Neuropathy with Nucleoside Antiretrovirals

    Unknown

  • Changes in hematologic parameters and efficacy of thymidine analogue-based, highly active antiretroviral therapy: a meta-analysis of six prospective, randomized, comparative studies.

    Graeme Moyle;Will Sawyer;Matthew Law;Janaki Amin

  • Proof of Activity with AMD11070, an Orally Bioavailable Inhibitor of CXCR4-Tropic HIV Type 1

    Graeme Moyle;Edwin DeJesus;Marta Boffito;Rebecca S. Wong

  • Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations.

    Bonaventura Clotet;François Raffi;David Cooper;Jean François Delfraissy

Frequent Co-Authors

Brian Gazzard
Brian Gazzard St Bartholomew's Hospital
Marta Boffito
Marta Boffito Imperial College London
Mark Nelson
Mark Nelson University of Vermont
David Back
David Back University of Liverpool
Anton Pozniak
Anton Pozniak London School of Hygiene & Tropical Medicine
Saye Khoo
Saye Khoo University of Liverpool
Paul E. Sax
Paul E. Sax Brigham and Women's Hospital
Edwin DeJesus
Edwin DeJesus Hanover University of Applied Sciences and Arts
Martin Fisher
Martin Fisher University of Sussex
Joseph J. Eron
Joseph J. Eron University of North Carolina at Chapel Hill

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in expanding their microbiology studies, pursuing related online degrees offers flexibility and diverse career opportunities. Many programs, including some accredited online MPH programs easy to get into, provide accessible pathways to public health careers that complement microbiology knowledge.

Career options extend beyond traditional microbiology roles. For example, becoming a child specialist salary can be an attractive route for those focused on pediatric health and development, often aligning with biology and health science backgrounds.

Additionally, for individuals with non-traditional backgrounds or unique challenges, exploring the best degree for felons can open doors in healthcare fields, helping break barriers and build rewarding careers.

Another rapidly growing career pathway is becoming a functional medicine nurse, which blends holistic health practices with scientific knowledge — a path well-suited for those with a background in microbiology or health sciences.

Best Scientists Citing Graeme Moyle

Trending Scientists

Recently Published Articles